This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Prescribing information is available by clicking the links at the bottom of the page

The Continuing Role of Secondary Care in Lipid Optimisation Post-ACS

Length: 6:59

Dr Rani Khatib discusses the reasons why post-MI secondary prevention clinics should be established, explains the Leeds cardiometabolic medicines optimisation pathway and their multidisciplinary innovative medicines clinic for PCSK9i & statin intolerance, the benefits to patients and healthcare system, and the challenges to overcome.

Videos From the Same Series

Implementing Artifical Intelligence to Risk Stratify, Manage and Refer Patients | Praluent® (alirocumab)

What's the Future of Secondary Care Lipid Services | Praluent® (alirocumab)

Strengthening the Interface between Primary and Secondary Care | Praluent® (alirocumab)

1/3

Implementing Artifical Intelligence to Risk Stratify, Manage and Refer Patients | Praluent® (alirocumab)

What's the Future of Secondary Care Lipid Services | Praluent® (alirocumab)

Strengthening the Interface between Primary and Secondary Care | Praluent® (alirocumab)

Get in touch with the Dyslipidaemia Team

MAT-XU-2300475 (v4.0) Date of Preparation: March 2024